OBJECTIVE: Concerns about increased breast cancer risk with estrogen and progestin therapy have led to an increased interest in progestin alternatives. The main objective of this study was to determine if bazedoxifene acetate (BZA), a new selective estrogen receptor modulator, will antagonize the proliferative and transcriptional effects of conjugated equine estrogens (CEE) in the breast. METHODS: As part of a 20-month preclinical trial, 95 ovariectomized cynomolgus macaques (Macaca fascicularis) were randomized to receive no treatment or treatment with BZA (20 mg/d), CEE (0.45 mg/d), or BZA and CEE in combination (women's daily equivalent doses). The data presented here include breast effects after 6 months of treatment. Endpoints included histomorphometry, histopathological evaluations, gene microarray assays, polymerase chain reaction quantification of specific estrogen receptor α (ER-α) activity markers, and immunohistochemical detection of sex steroid receptors, and the proliferation marker Ki67. RESULTS: BZA + CEE and BZA resulted in significantly less total epithelial density, lobular enlargement, and Ki67 immunolabeling in the terminal ducts compared with CEE alone (P < 0.05 for all). The addition of BZA to CEE antagonized the expression of ER-α-regulated genes such as GREB1 and TFF1 (P < 0.01 for both), whereas BZA alone had minimal effects on ER-α-mediated transcriptional activity. BZA and BZA + CEE did not significantly up-regulate genes related to cell cycle progression and proliferation. BZA with and without CEE also resulted in less lobular and terminal duct ER-α immunolabeling compared with control and CEE (P < 0.0001 for all). CONCLUSIONS: These findings demonstrate that BZA given at a clinically relevant dose is an estrogen antagonist in the breast, supporting the idea that CEE + BZA may provide a lower breast cancer risk profile compared with traditional estrogen + progestin therapies.
OBJECTIVE: Concerns about increased breast cancer risk with estrogen and progestin therapy have led to an increased interest in progestin alternatives. The main objective of this study was to determine if bazedoxifene acetate (BZA), a new selective estrogen receptor modulator, will antagonize the proliferative and transcriptional effects of conjugated equine estrogens (CEE) in the breast. METHODS: As part of a 20-month preclinical trial, 95 ovariectomized cynomolgus macaques (Macaca fascicularis) were randomized to receive no treatment or treatment with BZA (20 mg/d), CEE (0.45 mg/d), or BZA and CEE in combination (women's daily equivalent doses). The data presented here include breast effects after 6 months of treatment. Endpoints included histomorphometry, histopathological evaluations, gene microarray assays, polymerase chain reaction quantification of specific estrogen receptor α (ER-α) activity markers, and immunohistochemical detection of sex steroid receptors, and the proliferation marker Ki67. RESULTS:BZA + CEE and BZA resulted in significantly less total epithelial density, lobular enlargement, and Ki67 immunolabeling in the terminal ducts compared with CEE alone (P < 0.05 for all). The addition of BZA to CEE antagonized the expression of ER-α-regulated genes such as GREB1 and TFF1 (P < 0.01 for both), whereas BZA alone had minimal effects on ER-α-mediated transcriptional activity. BZA and BZA + CEE did not significantly up-regulate genes related to cell cycle progression and proliferation. BZA with and without CEE also resulted in less lobular and terminal duct ER-α immunolabeling compared with control and CEE (P < 0.0001 for all). CONCLUSIONS: These findings demonstrate that BZA given at a clinically relevant dose is an estrogen antagonist in the breast, supporting the idea that CEE + BZA may provide a lower breast cancer risk profile compared with traditional estrogen + progestin therapies.
Authors: T J de Villiers; A A Chines; S Palacios; P Lips; A Z Sawicki; A B Levine; C Codreanu; N Kelepouris; J P Brown Journal: Osteoporos Int Date: 2010-06-10 Impact factor: 4.507
Authors: Andrea Z LaCroix; Rowan T Chlebowski; JoAnn E Manson; Aaron K Aragaki; Karen C Johnson; Lisa Martin; Karen L Margolis; Marcia L Stefanick; Robert Brzyski; J David Curb; Barbara V Howard; Cora E Lewis; Jean Wactawski-Wende Journal: JAMA Date: 2011-04-06 Impact factor: 56.272
Authors: Stuart L Silverman; Claus Christiansen; Harry K Genant; Slobodan Vukicevic; José R Zanchetta; Tobie J de Villiers; Ginger D Constantine; Arkadi A Chines Journal: J Bone Miner Res Date: 2008-12 Impact factor: 6.741
Authors: Judy S Crabtree; Bryan J Peano; Xiaochun Zhang; Barry S Komm; Richard C Winneker; Heather A Harris Journal: Mol Cell Endocrinol Date: 2008-02-12 Impact factor: 4.102
Authors: Charles E Wood; Thomas B Clarkson; Haiying Chen; Timothy D Veenstra; Xia Xu; Latanya Scott; J Mark Cline Journal: Menopause Date: 2008 Sep-Oct Impact factor: 2.953
Authors: Bryan J Peano; Judy S Crabtree; Barry S Komm; Richard C Winneker; Heather A Harris Journal: Endocrinology Date: 2008-11-20 Impact factor: 4.736
Authors: Carol J Fabian; Lauren Nye; Kandy R Powers; Jennifer L Nydegger; Amy L Kreutzjans; Teresa A Phillips; Trina Metheny; Onalisa Winblad; Carola M Zalles; Christy R Hagan; Merit L Goodman; Byron J Gajewski; Devin C Koestler; Prabhakar Chalise; Bruce F Kimler Journal: Cancer Prev Res (Phila) Date: 2019-08-16
Authors: Thomas B Clarkson; Kelly F Ethun; Haiying Chen; Debbie Golden; Edison Floyd; Susan E Appt Journal: Menopause Date: 2013-03 Impact factor: 2.953
Authors: Kelly F Ethun; Charles E Wood; J Mark Cline; Thomas C Register; Susan E Appt; Thomas B Clarkson Journal: Menopause Date: 2013-07 Impact factor: 2.953
Authors: Thomas B Clarkson; Kelly F Ethun; Nicholas M Pajewski; Debbie Golden; Edison Floyd; Susan E Appt Journal: Menopause Date: 2014-01 Impact factor: 2.953